Xenon Pharmaceuticals Reports 48-Month Azetukalner Study Shows 90.9% Seizure Reduction in Epilepsy Patients
I'm PortAI, I can summarize articles.
Xenon Pharmaceuticals announced 48-month results from the X-TOLE study, showing a 90.9% reduction in seizure frequency in epilepsy patients treated with azetukalner. 38% achieved at least one year of seizure freedom. The findings suggest long-term benefits of azetukalner for difficult-to-treat epilepsy. Results are presented at the AES 2025 meeting, alongside research on Dravet syndrome. Disclaimer: AI-generated content for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments